Price Alert

Glaukos Corporation (GKOS)

NYSE: GKOS · Real-Time Price · USD

91.06

-0.73 (-0.80%)

At close: Aug 14, 2025, 3:59 PM

89.50

-1.71%

After-hours: Aug 14, 2025, 06:44 PM EDT

-0.80% (1D)

Bid	83.54
Market Cap	5.22B
Revenue (ttm)	432.95M
Net Income (ttm)	-92.79M
EPS (ttm)	-1.61
PE Ratio (ttm)	-56.56
Forward PE	2827
Analyst	Buy

Ask	100
Volume	555,196
Avg. Volume (20D)	1,001,208
Open	91.22
Previous Close	91.79
Day's Range	88.94 - 91.36
52-Week Range	77.10 - 163.71
Beta	0.78

About GKOS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GKOS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for GKOS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Glaukos Corporation is scheduled to release its earnings on Nov 3, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

-8.46%

Glaukos shares are trading lower. The company repo... Unlock content with Pro Subscription

3 months ago

-11.36%

Glaukos shares are trading lower after the company reported Q1 financial results. Additionally, Needham cut its price target on the stock from $176 to $115.

News

2 days ago · businesswire.com

Glaukos Announces Participation in Wells Fargo Healthcare Conference

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

2 weeks ago · fool.com

Glaukos (GKOS) Q2 Revenue Jumps 30%

Glaukos (GKOS -8.55%), a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of...

2 weeks ago · zacks.com

GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised

Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.

2 weeks ago · seekingalpha.com

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Glaukos Corporation (NYSE:GKOS ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Alex R. Thurman - Senior VP & CFO Christopher William Lewis - Vice President of Investor...

2 weeks ago · zacks.com

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.52 per share a year ago.